ClinicalTrials.gg
RecruitingNCT07298005SON4PEMUpdated Aug 18, 2026

Sonlicromanol in Post-COVID

A Phase 2 interventional study of Sonlicromanol and Placebo in Post COVID Condition, sponsored by Michele van Vugt. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Michele van Vugt · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands — 6 open to participants now, 6 under way, 3 of them phase 3. Post-Acute COVID-19 Syndrome · Netherlands.

Started
2026
with 2 others
Phase 2
2 of 15
2 open now
Registered
14th of 15
by date
Lead sponsor
1 of 15
Michele van Vugt

Among the 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands, this one is one of 3 that started in 2026, is one of 2 in phase 2, and was the 14th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

6 of the 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands, or all of them as a file.
02

Study summary

The aim of this randomized, double-blind, placebo-controlled, phase II trial, is to study the effect of sonlicromanol on fatigue in patients with post-COVID who experience post-exertional malaise (PEM).

03

Conditions studied

  • Post COVID Condition
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Post COVID according to WHO criteria and verified by post COVID physician
  • Post-exertional malaise (PEM) according to DSQ-PEM questionnaire
  • Bell's disability score 20-70%
  • Mild initial SARS-CoV-2 infection (no hospitalisation)
  • WHO performance score of 0 before initial SARS-CoV-2 infection

Exclusion criteria

Exclusion Criteria:

  • Patients at risk for cardiac conduction disorders
  • History of clinical significant gastro-intestinal surgery or dysmotility that impairs the adsorption of the IMP
  • respiratory or cardiovascular disease
  • Unstable neurological disease
  • Clinically significant active psychiatric disorder that requires treatment
  • History of substance abuse
  • Active within the past 5 years
  • History of solid organ transplantation
  • Active , or C infection
  • \< 18.5 or > 35
  • Pregnancy or breastfeeding
  • Clinically relevant laboratory test value outside the reference range
  • Use of the following medication, unless stable for at least one month before study and remaining stable throughout the study: (multi)vitamins, co-enzyme Q10, Vitamin E, riboflavin, amino acids, antioxidant supplements and any medication negatively influencing mitochondrial functioning (including but not limited to valproic acid, glitazones, statins, antivirals, amiodarone and NSAIDs)
  • Use of the following medication: any moderate or strong Cytochrome P450 (CYP)3A4 inhibitors (all 'conazoles-anti-fungals', HIV antivirals, grapefruit), strong inducers ((including HIV antivirals, carbamazepine, phenobarbital, phenytoin, rifampicin, St. John's wort, pioglitazone, troglitazone) or any medication metabolized by CYP3A4 with a narrow therapeutic index, medication known to be substrate of Organic Cation Transporter 1 (OCT1) and organic cation transporter 2 (OCT2) or strong P-glycoprotein inhibitors (including amiodarone, azithromycin, captopril, clarithromycin, cyclosporine, piperine, quercetin, quinidine, quinine, reserpine, ritonavir, tariquidar, and verapamil).
  • Use of any medication known to affect cardiac repolarization unless at screening is normal during stable treatment for a period of two weeks, or 5 half-lives
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Drug: Sonlicromanol

  • Placebo comparator
    Placebo group

    Drug: Placebo

Interventions

  • DrugTroloxStudies of TroloxTrolox pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sonlicromanol 90mg twice daily for 13 weeks

  • DrugPlacebo

    Placebo twice daily for 13 weeks

06

What researchers measure

Primary outcomes

  1. Fatigue

    Post-COVID related fatigue measured with the Fatigue Assessment Scale (FAS), a 10-item questionnaire measuring physical/mental fatigue (ranging from 10-50), with scores \<22 indicating no fatigue, 22-34 mild-to-moderate, and ≥35 severe fatigue

    Time frame: Between group differences at week 13

Secondary outcomes

  1. Muscle strength

    Muscle strength measured with the Repeated Handgrip Strength of the dominant hand

    Time frame: Between group differences at week 13

  2. Cognitive function

    Post-COVID related cognitive function measured with the PROMIS cognitive function SF 8a, measures self-perceived cognitive abilities, with scores converted to a T-score (mean 50, SD 10), where higher scores indicate better functioning

    Time frame: Between group differences at week 13

  3. Health related quality of life

    Health related quality of life measured with the SF-36 questionnaire with scores ranging from 0-100, where higher scores indicate better quality of life

    Time frame: Between group differences at week 13

  4. Fatigue

    Post-COVID related fatigue measured with the NeuroQoL SF Fatigue, resulting in a T-score (mean 50, SD 10) where higher scores mean more fatigue

    Time frame: Between group differences at week 13

07

Study locations

1 of 1 sites recruiting
  • Amsterdam University Medical Center, Location Academic Medical Center (AMC)
    Amsterdam, North Holland 1105 AZ, Netherlands
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Feb 2027, 10 months after the start.

Of 46 non-industry phase 2 interventional studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 24. This study's planned 10 months is below that.

Counting every sponsor, half of 63 studies reached it within 17 months; a quarter within 12 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Dec 22, 2025
StartActual
Apr 3, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Mar 2027
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07298005
Lead sponsor
Michele van Vugt
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development, Khondrion BV
Responsible party
Michele van Vugt (Prof. Dr. M. van Vugt, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Sponsor-investigator
First posted
Dec 22, 2025
Start date
Apr 3, 2026
Primary completion
Feb 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Aug 18, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trolox

Start the discussion